Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201

[1]  W. Berdel,et al.  A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia , 2016, European journal of haematology.

[2]  R. Larson,et al.  Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials , 2016, American journal of hematology.

[3]  C. Récher,et al.  Impact of obesity in favorable‐risk AML patients receiving intensive chemotherapy , 2016, American journal of hematology.

[4]  M. Labopin,et al.  Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. , 2014, Leukemia research.

[5]  J. Maciejewski,et al.  Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight , 2013, American journal of hematology.

[6]  D. Neuberg,et al.  Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia , 2013, American journal of hematology.

[7]  J. Mitri,et al.  Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. , 2012, Leukemia research.

[8]  E. Estey,et al.  Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia , 2012, Haematologica.

[9]  A. Hyland,et al.  Is obesity a prognostic factor for acute myeloid leukemia outcome? , 2012, Annals of Hematology.

[10]  L. Lashinger,et al.  The growing challenge of obesity and cancer: an inflammatory issue , 2011, Annals of the New York Academy of Sciences.

[11]  P. Grigsby,et al.  The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy , 2011, Cancer.

[12]  T. Naoe,et al.  Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. , 2011, Blood.

[13]  T. Naoe,et al.  A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML 201 Study , 2011 .

[14]  L. Purton,et al.  Effects of the bone marrow microenvironment on hematopoietic malignancy. , 2011, Bone.

[15]  J. Stockman.  Mortality in Overweight and Underweight Children with Acute Myeloid Leukemia , 2006 .

[16]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[17]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[18]  A. Norman,et al.  Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? , 1998, European journal of cancer.